ADMA Biologics (ADMA) Reports Q4 Loss of $0.58
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
ADMA Biologics Reports Year End 2015 Financial Results, Accomplishments and Upcoming Milestones
March 23, 2016 4:27 PM EDTRAMSEY, N.J., March 23, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2015, and outlined the companys 2015 accomplishments and anticipated milestones for 2016.
During 2015 we achieved several meaningful milestones, including the filing and acceptance of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for our lead product candidate, RI-002, received patent protection for... More
